Cedra names two new directors
They join business development in generics and automation for the bioanalytical division
Pottier has more than 17 years within the sales and marketing sector of the contract research organisation (CRO) market.
Prior to joining Cedra, Pottier held positions with Novum Pharmaceutical Research Services and PRACS Institute/Cetero Research relating to business development.
Lloyd has more than 22 years of experience in developing and automating analytical and bioanalytical processes. His specific expertise is in automation systems and analytical instrument development, bioanalytical chemistry, in vitro DMPK studies, software programming and application, statistics, chemometrics and GLP requirements.
Prior to joining Cedra, Lloyd led the automation group at Pfizer, previously known as Wyeth Research. He has held previous positions at DuPont Merck Pharmaceutical Company and Glaxo.
You may also like
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Titan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Regulatory
Pheno Therapeutics secures two patents for neurological drug pipeline
The Edinburgh-based biotech has strengthened its intellectual property portfolio for two selective GPR17 antagonists, including its lead multiple sclerosis candidate, PTD802, which has US and UK regulatory clearance to enter clinical trials
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target
Collaboration combines cell-free protein synthesis, proprietary nanodisc technology and cryo-electron microscopy (cryo-EM) for high-resolution structural analysis of a G protein-coupled receptor (GPCR)
Research & Development
Evotec secures $2.9m grant to advance stem cell-based drug safety testing
The three-year Gates Foundation grant will support Evotec's human induced pluripotent stem cell platform, helping global health researchers identify potential developmental toxicity risks earlier in drug discovery